A Phase 1 study of <scp>GDC</scp> ‐0134, a dual leucine zipper kinase inhibitor, in <scp>ALS</scp>-Reference-Cited by-同舟云学术

A Phase 1 study of GDC ‐0134, a dual leucine zipper kinase inhibitor, in ALS

Published:2022-01 Issue:1 Volume:9 Page:50-66
ISSN:2328-9503
Container-title:Annals of Clinical and Translational Neurology
language:en
Short-container-title:Ann Clin Transl Neurol

Author:

Katz Jonathan S.¹,Rothstein Jeffrey D.²,Cudkowicz Merit E.³,Genge Angela⁴,Oskarsson Björn⁵,Hains Avis B.⁶,Chen Chen⁶,Galanter Joshua⁶,Burgess Braydon L.⁶,Cho William⁶,Kerchner Geoffrey A.⁷,Yeh Felix L.⁶,Ghosh Arundhati Sengupta⁶,Cheeti Sravanthi⁶,Brooks Logan⁶,Honigberg Lee⁶,Couch Jessica A.⁶,Rothenberg Michael E.⁶,Brunstein Flavia⁶,Sharma Khema R.⁸,Berg Leonard⁹,Berry James D.¹⁰,Glass Jonathan D.¹¹^ORCID

Affiliation:

1. Forbes Norris MDA/ALS Research Center, California Pacific Medical Center San Francisco California USA

2. Johns Hopkins Hospital Baltimore Maryland USA

3. Sean M. Healey and AMG Center for ALS Massachusetts General Hospital, Harvard Medical School Boston Massachusetts USA

4. Montreal Neurological Institute & Hospital Montreal QC Canada

5. Mayo Clinic Jacksonville Florida USA

6. Genentech, Inc. South San Francisco California USA

7. F. Hoffmann‐La Roche, Ltd. Basel Switzerland

8. University of Miami Hospital (CRC) Miami Florida USA

9. UMC Utrecht Utrecht The Netherlands

10. Neurological Clinical Research Institute Boston Massachusetts USA

11. Emory University School of Medicine Atlanta Georgia USA